This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Goldman JM, Melo JV . Chronic myeloid leukemia – advances in biology and new approaches to treatment. N Engl J Med 2003; 349: 1451–1464.
Marmont AM, Horowitz MM, Gale RP, Sobocinski K, Ash RC, van Bekkum DW et al. T-cell depletion of HLA-identical transplants in leukemia. Blood 1991; 78: 2120–2130.
Luznik L, Fuchs EJ . Donor lymphocyte infusions to treat hematologic malignancies in relapse after allogeneic blood or marrow transplantation. Cancer Control 2002; 9: 123–137.
Molldrem JJ, Lee PP, Wang C, Felio K, Kantarjian HM, Champlin RE et al. Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia. Nat Med 2000; 6: 1018–1023.
Yotnda P, Firat H, Garcia-Pons F, Garcia Z, Gourru G, Vernant JP et al. Cytotoxic T cell response against the chimeric p210 BCR-ABL protein in patients with chronic myelogenous leukemia. J Clin Invest 1998; 101: 2290–2296.
Norbury LC, Clark RE, Christmas SE . b3a2 BCR-ABL fusion peptides as targets for cytotoxic T cells in chronic myeloid leukaemia. Br J Haematol 2000; 109: 616–621.
Butt NM, Rojas JM, Wang L, Christmas SE, Abu-Eisha HM, Clark RE . Circulating bcr-abl-specific CD8+ T cells in chronic myeloid leukemia patients and healthy subjects. Haematologica 2005; 90: 1315–1323.
Babatz J, Rollig C, Lobel B, Folbrecht G, Haack M, Gunther H et al. Induction of cellular immune responses against carcinoembryonic antigen in patients with metastatic tumors after vaccination with altered peptide ligand-loaded dendritic cells. Cancer Immunol Immun 2006; 55: 268–276.
Kiessling A, Schmitz M, Stevanovic S, Weigle B, Holig K, Fussel M et al. Prostate stem cell antigen: identification of immunogenic peptides and assessment of reactive CD8+ T cells in prostate cancer patients. Int J Cancer 2002; 102: 390–397.
Falkenburg JH, Wafelman AR, Joosten P, Smit WM, van Bergen CA, Bongaerts R et al. Complete remission of accelerated phase chronic myeloid leukemia by treatment with leukemia-reactive cytotoxic T lymphocytes. Blood 1999; 94: 1201–1208.
Elmaagacli AH, Peceny R, Steckel N, Trenschel R, Ottinger H, Grosse-Wilde H et al. Outcome of transplantation of highly purified peripheral blood CD34+ cells with T-cell add-back compared with unmanipulated bone marrow or peripheral blood stem cells from HLA-identical sibling donors in patients with first chronic phase chronic myeloid leukemia. Blood 2003; 101: 446–453.
Acknowledgements
We would like to thank Bärbel Löbel, Diana Döhler, Verona Schwarze, Anja Maiwald and Anja Zenkel for the excellent technical assistance as well as Michelle Meredyth-Stewart for proof-reading of the manuscript. This work was supported in part by the Deutsche Krebshilfe Grant 70-2755 (MB and CT) and 70-2980 (MB and MS).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Bornhauser, M., Thiede, C., Babatz, J. et al. Infusion of bcr/abl peptide-reactive donor T cells to achieve molecular remission of chronic myeloid leukemia after CD34+ selected allogeneic hematopoietic cell transplantation. Leukemia 20, 2055–2057 (2006). https://doi.org/10.1038/sj.leu.2404383
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.leu.2404383